KLRS · Kalaris Therapeutics Inc

Kalaris Therapeutics’ Q1 2026 financial results reflect continued investment in the clinical development of TH103, its lead candidate for neovascular age-related macular degeneration. Net loss increased to $10.9 million (vs. $10.2 million in Q1 2025), driven primarily by a $1.6 million year-over-year rise in research and development expenses — attributed explicitly to expanded clinical trial activity, including opening additional investigational sites and enrolling patients in the Phase 1b/2 study. General and administrative expenses remained flat at $4.3 million. Notably, diluted EPS improved to ($0.46) from ($2.52) year-over-year, reflecting a significant increase in weighted-average shares outstanding (23.7M vs. 4.1M), likely due to prior financing or equity-based compensation. The company’s cash position declined to $104.9 million as of March 31, 2026 — down $13.1 million from December 31, 2025 — with management attributing the decrease to operating cash outflows. This cash balance is stated to be sufficient to fund operations into the fourth quarter of 2027 and through key clinical milestones, including preliminary data readout from the Phase 1b/2 study in 1H 2027 and initiation of planned Phase 3 trials by year-end 2027. CEO Andrew Oxtoby emphasized progress in manufacturing (new batch with enhanced purity) and patient screening, underscoring that the Phase 1b/2 trial is designed to inform dose selection for Phase 3. Given the absence of revenue, the financials are purely expense- and cash-runway-driven, making the timing and quality of upcoming clinical data the primary near-term value catalyst for investors.